Open AccessInherited thrombophilic risk factors in Serbian breast cancer patients
Author(s) -
Iva Pruner,
Branko Tomić,
M Dragojević,
Maja Gvozdenov,
Mirjana Kovač,
Dragica Radojković,
Valentina Djordjević
Publication year - 2019
Publication title -
genetika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.24
H-Index - 15
eISSN - 1820-6069
pISSN - 0534-0012
DOI - 10.2298/gensr1902463p
Subject(s) - breast cancer , methylenetetrahydrofolate reductase , medicine , cancer , thrombosis , oncology , genotype , cohort , gastroenterology , etiology , gynecology , genetics , gene , biology
Breast cancer is the leading cause of cancer-related death among women. An increased burden of thrombotic events among breast cancer patients, leading to higher mortality and morbidity rates, is well established. There are a number of genetic risk factors associated with thrombosis, but their contribution to thrombotic tendencies in patients with cancer is not completely elucidated. We aimed to investigate possible role of FV Leiden, FII G20210A, MTHFR C677T and PAI-1 4G/5G gene variants in etiopathology of breast cancer and accompanying thrombosis in cohort of Serbian patients. Our study included 316 subject divided in three groups: breast cancer patients with (97) or without (99) accompanying thrombosis and healthy control group (120). According to our results, the prevalence for all four prothrombotic gene variants were similar in cancer patients with and without thrombosis and no statistically significant difference was observed between these groups. We detected lower frequency of MTHFR 677TT genotype in breast cancer patients when compared to control group (P=0.014; OR=0.145 (95%CI 0.031-0.679)), indicated that MTHFR C677T homozygosity could play a protective role in breast cancer susceptibility. Our study noted the lack of association between common prothrombotic gene variants and increased prothrombotic risk in Serbian breast cancer patients. Also, our results point out possible role of MTHFR 677TT genotype in etiology of breast cancer, but further studies on larger cohort of patients are needed.